Journal of Nutrition LabDiet, Your World of Nutritional Answers

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


J. Nutr. First published August 26, 2009; doi:10.3945/jn.109.108001
Journal of Nutrition, doi:10.3945/jn.109.108001
Vol. 139, No. 10, 1833-1838, October 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
139/10/1833    most recent
jn.109.108001v1
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Allred, K. F.
Right arrow Articles by Allred, C. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allred, K. F.
Right arrow Articles by Allred, C. D.
© 2009 American Society for Nutrition


Biochemical, Molecular, and Genetic Mechanisms

Trigonelline Is a Novel Phytoestrogen in Coffee Beans1,2

Kimberly F. Allred3, Katarina M. Yackley3, Jairam Vanamala4,5 and Clinton D. Allred3,4,*

3 Department of Nutrition and Food Science and 4 Institute for Obesity Research and Program Evaluation, Texas A&M University, College Station, TX 77843; and 5 Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, CO 80523

Drinking coffee has been associated with the development of several endocrine-related cancers. The interpretation of these data has often been limited to the role that caffeine plays. Trigonelline (Trig), a niacin-related compound, is a natural constituent of coffee accounting for ~1% dry matter in roasted beans. Studies exploring the effects of this bioactive compound on mammalian cells are limited. The initial purpose of our studies was to determine whether Trig alters the actions of estradiol (E2), using proliferation of estrogen-dependent human breast cancer (MCF-7) cells as a model system. When cells were cotreated with suboptimal doses of E2 (10 pmol/L) and Trig (100 pmol/L), an additive enhancement of MCF-7 growth was observed. In the absence of E2, Trig stimulated MCF-7 cell proliferation in a dose-responsive manner and significantly enhanced cell growth at concentrations as low as 100 pmol/L. Cotreatment of MCF-7 cells with Trig and ICI 182,780, an estrogen receptor (ER) antagonist, inhibited Trig-induced cell proliferation. Trig treatment also induced activation of estrogen response element reporter assays in MCF-7 cells and increased expression of ER target genes (pS2, progesterone receptor, and cyclin D1) similar to E2. While our data demonstrate that Trig activates the ER, competitive binding assays showed that Trig does not compete E2 off of the ER at any concentration. This suggests that Trig is activating the ER through a separate mechanism. Collectively, these data demonstrate that Trig even at low concentrations stimulates MCF-7 cell growth and that this effect is mediated through ER, clearly identifying Trig as a novel phytoestrogen.


* To whom correspondence should be addressed. E-mail:callred{at}tamu.edu.

Manuscript received 28 March 2009. Initial review completed 20 April 2009. Revision accepted 24 July 2009.

Published online 26 August 2009.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Copyright © 2009 by American Society for Nutrition